$Nektar Therapeutics(NKTR)$ Congratulations to trader who bought it on pre market and earn profit for day trading. Simple rule for trading momentum. - Lock on 20% to 40% - Do not be greedy in trading momentum. 2 simple rule , 2 rule to profit Follow me , follow momentum
U.S. stock futures declined Monday morning as investors returned from a holiday weekend and geared up for another busy week of corporate earnings results. Market Snapshot At 7:50 a.m. ET, Dow e-minis were down 19 points, or 0.06%, S&P 500 e-minis were down 8 points, or 0.18%, and Nasdaq 100 e-minis were down 39.25 points, or 0.28%. Pre-Market Movers $Twitter(TWTR)$ – Twitter shares jumped 4.5% in the premarket after the company’s board of directors adopted a so-called poison pill to preventTesla(TLSA) CEO Elon Musk from increasing his stake in the company past 15%. That follows Musk’s $54.20 per share bid for Twitter last week. $Sirius XM(SIRI)$ – The satellite radio operator’s stock fell 2% in pr
Daily Ratings | ZM being Upgraded, ZNGA Got Downgraded
Hi Tigers, Below are the Analyst Rating data of stocks sourced from benginza.com. Hope this information will help you to check your holdings by the reference Analysts Ratings. A stock rating is a measure of the expected performance of a stock in a given time period. Analysts and brokerage firms often use ratings when issuing stock recommendations to stock traders. The Companies Rate Ratings are as Below: TOP 5 Upgrades are: $Zoom(ZM)$$Turquoise Hill Resources(TRQ)$$Washington Federal(WAFD)$
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.